Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 2
Submit an article Journal homepage
86
Views
69
CrossRef citations to date
0
Altmetric
Review

Novel agents for the treatment of resistant Gram-positive infections

Neil Woodford ARMRL, CPHL, 61 Colindale Avenue, London NW9 5HT, UK. [email protected]
Pages 117-137 | Published online: 02 Mar 2005

Bibliography

  • VAN VALEN L: A new evolutionary law Evolutionary Theory (1973) 1:1–30.
  • UTTLEY AHC, COLLINS CH, NAIDOO J, GEORGE RC: Vancomycin-resistant enterococci. Lancet (1988) 1:57–58.
  • LECLERCQ R, DERLOT E, DUVAL J, COURVALIN P: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterocaccus faecium. N Engl. j Med. (1988) 319:157–161.
  • HIRAMATSU K, HANAKI H, INO T et al.: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. _J. Antimicrob. Chemother. (1997) 40:135–136.
  • SIEVERT DM, BOULTON ML, STOLTMAN G et al.: Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR -Morbidity Mortality Weekly Report (2002) 51:565–567.
  • ••The first report of a clinical S. aureus strainthat acquired enterococcal glycopeptide resistance genes.
  • MILLER D, URDANETA V, WELTMAN A, PARK S: Vancomycin-resistant Staphylococcus aureus- Pennsylvania, 2002. MMWR - Morbidity Mortality Weekly Report (2002) 51:902.
  • ••The second report of a clinical S. aureusstrain that acquired enterococcal glycopeptide resistance genes.
  • WERNER G, KLARE I, WITTE W: Molecular analysis of streptogramin resistance in enterococci. mt. j Med. Microbial (2002) 292:81–94.
  • SOLTANI M, BEIGHTON D, PHILPOTT-HOWARD J, WOODFORD N: Mechanisms of resistance to quinupristin/dalfopristin among isolates of Enterocaccus faecium from animals, raw meat and hospital patients in Western Europe. Antimicrob. Agents Chemother. (2000) 44:433–436.
  • PRYSTOWSKY J, SIDDIQUI F, CHOSAYJ et al.: Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. (2001) 45:2154–2156.
  • ZURENKO GE, TODD WM, HAFKIN B et al: Development of linezolid-resistant Enterocaccus faecium in two compassionate use programme patients treated with linezolid. Proc. Abstr: 39th Interscience Conference Antimicrob. Agents Chemother. (1999):118 (Abstract 848).
  • WOODFORD N, TYSALL L, AUCKLAND C et al.: Detection of oxazolidinone-resistant Enterocaccus faecalis and Enterocaccus faecium strains by real-time PCR and PCR-restriction fragment polymorphism analysis. I Chit. 11/licrobial. (2002) 40:4298–4300.
  • TSIODRAS S, GOLD HS, SAKOULAS G et al: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358:207–208.
  • ENNE V, HOWE RA, WALSH TR, MUTNICK AH, JONES RN: Initial descriptions of linezolid resistance in Staphylococcus epidermidis and Streptococcus oralis: report from the SENTRY antimicrobial surveillance program. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002) (Abstract LB–10).
  • MCHENNEY MA, HOSTED TJ, DEHOFF BS, ROSTECK PR, JR., BALTZ RH: Molecular cloning and physical mapping of the daptomycin gene cluster from Streptornyces roseasporus. I Bacterial (1998) 180:143–151.
  • TALLY FP, ZECKEL M, WASILEWSKI MM et al.: Daptomycin: a novel agent for Gram-positive infections. Expert. Opin. Investig. Drugs (1999) 8:1223–1238.
  • KING A, PHILLIPS I: The in vitro activityof daptomycin against 514 Gram-positive aerobic clinical isolates. _J. Antimicrob. Chemother. (2001) 48:219–223.
  • TALLY FP, DEBRUIN MF: Development of daptomycin for Gram-positive infections. Antimicrob. Chemother. (2000) 46:523–526.
  • SILVERMAN JA: Mode of action and mechanisms of resistance to the lipopeptide daptomycin. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002):454 (Abstract 615).
  • TRACZEWSKI MM, BROWN SD, BARRY AL: Evaluation of daptomycin susceptibility by the Etest method using Etest strips with added calcium. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002):128 (Abstract D–36).
  • BARRY AL, FUCHS PC, BROWN SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1919–1922.
  • AKINS RL, RYBAK MJ: In vitro activities of daptomycin, arbekacin, vancomycin and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. (2000) 44:1925–1929.
  • RYBAK MJ, HERSHBERGER E, MOULDOVAN T, GRUCZ RG: In vitro activities of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin- intermediate and - resistant strains. Antimicrob. Agents Chemother. (2000) 44:1062–1066.
  • AKINS RL, RYBAK MJ: Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterocaccus faecium and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2001) 45:454–459.
  • CHAR, BROWN WJ, RYBAK MJ: Bactericidal activity of daptomycin, linezolid and quinupristin/dalfopristin against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002) (Abstract LB–11).
  • MARSHALL CG, BROADHEAD G, LESKIW BK, WRIGHT GD: D-Ala-D-ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc. Natl. Acad. Sci. USA (1997) 94:6480–6483.
  • MARSHALL CG, LESSARD IAD, PARK I-S, WRIGHT GD: Glycopeptide antibiotic resistance genes and glycopeptide-producing organisms. Antimicrob. Agents Chemother. (1998) 42:2215–2220.
  • SILVERMAN JA, OLIVER N, ANDREW T, LI T: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45:1799–1802.
  • MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8:1759–1773.
  • WOODFORD N: Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb. Drug Resist. (2001) 7:229–236.
  • CHOPRA I: N-alkyl-substituted glycopeptide antibiotics. Expert. Opin. Investig. Drugs (1997) 6:299–303.
  • LOUTIT JS: Mode of action and current status of the glycopeptide oritavancin. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002)455 (Abtstract 617).
  • GEM, CHEN Z, ONISHI HR etal.: Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science (1999) 284:507–511.
  • WALSH C: Deconstructing vancomycin. Science (1999) 284:442–443.
  • PATEL R, ROUSE MS, PIPER KE, COCKERILL FRI, STECKELBERG JM: In vitro activity of LY-333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus prieumardae. Diagn. Microbial Infect. Dis. (1998) 30:89–92.
  • JONES RN, BARRETT MS, ERWIN ME: In vitro activity and spectrum of LY-333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. (1997) 41:488–493.
  • BIAVASCO F, VIGNAROLI C, LUPIDI R et al.: In vitro antibacterial activity of LY-333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. (1997) 41:2165–2172.
  • FRAISE AP, ANDREWS J, WISE R: Activity of a new glycopeptide antibiotic (LY-333328) against enterococci and other resistant Gram-positive organisms. Antimicrob. Chemother. (1997) 40:423–425.
  • AESCHLIMANN JR, ALLEN GP, HERSHBERGER E, RYBAK MJ: Activities of LY-333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. (2000) 44:2991–2998.
  • SCHWALBE RS, MCINTOSH AC, QAIYUMI S et al.: In-vitro activity of LY-333328, an investigational glycopeptide, against enterococci and staphylococci. Antimicrob. Agents Chemother. (1996) 40:2416–2419.
  • MERCIER RC, STUMPO C, RYBAK MJ: Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY-333328), against Staphylococcus aureus and Enterocaccus faecium. j Antimicrob. Chemother. (2002) 50:19–24.
  • ARTHUR M, DEPARDIEU F, REYNOLDS P, COURVALIN P: Moderate-level resistance to glycopeptide LY-333328 mediated by genes of the vanA and vard3 clusters in enterococci. Antimicrob. Agents Chemother. (1999) 43:1875–1880.
  • MERCIER RC, HOULIHAN HH, RYBAK MJ: Pharmacodynamic evaluation of a new glycopeptide, LY-333328 and in vitro activity against Staphylococcus aureus and Enterocaccus faecium. Antimicrob. Agents Chemother. (1997) 41:1307–1312.
  • WILSON P, KOSHY C, MINASSIAN M: An LY-333328-dependent strain of Enterocaccus faecium isolated from a blood culture. j Antimicrob. Chemother. (1998) 42:406–407.
  • DE LA PENA A, CHIEN J, GEISER J etal.: Microbiological outcomes and pharmacokinetics of oritavancin in patients with bacteremia. Clin. ll/licrobial Infect. (2002) 8\(Suppl. 1) (Abstract P1091).
  • CANDIANI G, ABBONDI M, BORGONOVI M, ROMANO G, PARENTI F: In-vitro and in-vivo antibacterial activity of BI 397, a new semisynthetic glycopeptide antibiotic. Antimicrob. Chemother. (1999) 44:179–192.
  • JONES RN, BIEDENBACH DJ, JOHNSON DM, PFALLER MA: In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. j Chemother. (2001) 13:244–254.
  • LEFORT A, PAVIE J, GARRY L, CHAU F, FANTIN B: Activity of dalbavancin (BI-397) in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) susceptible or intermediate to glycopeptides (GISA). Proc. Abstr 42nd Interscience Conference Antimicrob. Agents Chemother. (2002)33 (Abstract B–278).
  • SOMNER EA, REYNOLDS PE: Inhibition of peptidoglycan synthesis by ramoplanin. Antimicrob. Agents Chemother. (1990) 34:413–419.
  • LO MC, MEN H, BRANSTROM A et al: A new mechanism of action proposed for ramoplanin. J. Am. Chem. Soc. (2000) 122:3540–3543.
  • WALKER S: Mode of action of the glycolipodepsipeptide ramoplanin. Proc. Abstr 42nd Interscience Conference Antimicrob. Agents Chemother. (2002)455 (Abstract 616).
  • HELM JS, CHEN L, WALKERS: Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan sysnthesis. j Am. Chem. Soc. (2002) 124:13970–13971.
  • CUDIC P, BEHENNA D, KRANZ J et al: Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin. Chem. Biol. (2002) 9:897.
  • BIAVASCO F, MANSO E, VARALDO PE: In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. (1991) 35:195–197.
  • BARTOLONI A, COLAO MG, ORSI A et al.: In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. j Antimicrob. Chemother. (1990) 26:627–633.
  • PRIVITERA P, COURVALIN P, PORRETTA A et al.: Prevalence of gastrointestinal carriage of glycopeptide-resistant enterococci in Europe. Gin ll/licrobial Infect. (2002) 8\(Suppl. 1) (Abstract P816).
  • WONG MT, KAUFFMAN CA, STANDIFORD HC et al.: Effective suppression of vancomycin-resistant Enterocaccus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Infect. Dis. (2001) 33:1476–1482.
  • BADEN LR, CRITCHLEY IA, SAHM DF et al.: Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. I Gun. Microbial (2002) 40:1160–1163.
  • GORDON KA, PFALLER MA, JONES RN: BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10 000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). 1 Antimicrob. Chernother. (2002) 49:851–855.
  • FUNG-TOMC JC, MINASSIAN B, KOLEK B et al.: Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chernother. (2000) 44:3351–3356.
  • INCE D, ZHANG X, SILVER LC, HOOPER DC: Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chernother. (2002) 46:3370–3380.
  • SHETTY N, WILSON AP: Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.j Antimicrob. Chernother. (2000) 46:633–638.
  • MILATOVIC D, SCHMITZ FJ, BRISSE S, VERHOEF J, FLUIT AC: In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob. Agents Chernother. (2000) 44:1102–1107.
  • BOZDOGAN B, KELLY L, JACOBS MR,APPELBAUM PC: Activity of DK-507k, a new fluoroquinolone, against quinolone non-susceptible Streptococcus prieurnortiae compared to ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin and sitafloxacin. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):189 (Abstract F–571).
  • SCHMITZ FJ, FLUIT AC, MILATOVIC D etal.: In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. I Antlinicrob. Chernother. (2000) 46:109–113.
  • YAZAKI A, NINO Y, KURAMOTO Y, OHSHITA Y: Structure-activity relationships of fluoroquinolones containing various heteroaromatics at N-1; WQ-3034/ABT-492 and its derivatives. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):183 (Abstract F–544).
  • ALMER LS, SHORTRIDGE VD, BUKOFZER S, FLAMM RK: Antimicrobial activity of ABT-492 and tentative disk test interpretive criteria. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):184 (Abstract F–550).
  • BARRY AL, TRACZEWSKI MM, BROWN SM: Relative potency of ABT-492 against selected bacterial pathogens and provisional disk test criteria. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):184 (Abstract F–548).
  • SMITH HJ, NICHOL KA, PALATNICK L et al.: In vitro activity of ABT-492 against ciprofloxacin-resistant Streptococcus prieurnordae compared to eight other drugs. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):184 (Abstract F–549).
  • CHOI KH, HONG JS, KIM SK et al: In-vitro and in-vivo activities of DW-116, a new fluoroquinolone. I Antimicrob. Chernother. (1997) 39:509–514.
  • CHOPRA I, ROBERTS M: Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbial Mal Biol. Rev. (2001) 65:232–260.
  • BUSH K, MACIELAG M, CLANCY J: `Superbugs': new antibacterials in the pipeline. Enterg. Drugs (2000) 5:347–365.
  • BLASI F, BRAGA P, CAZZOLA M, COSENTINI R, TARSIA P: Therapies in development for community-acquired pneumonia. Expert Opin. Investig. Drugs (2002) 11:545–552.
  • PATEL R, ROUSE MS, PIPER KE, STECKELBERG JM: In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneurnordae. Diagn. 11/licrobial Infect. Dis. (2000) 38:177–179.
  • GALES AC, JONES RN: Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbial. Infect. Dis. (2000) 36:19–36.
  • TUCKMAN M, PETERSEN PJ, PROJAN SJ: Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. (2000) 6:277–282.
  • GUAY GG, TUCKMAN M, ROTHSTEIN DM: Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pump. Antimicrob. Agents Chernother. (1994) 38:857–860.
  • HARTMANN PG, KOMPIS I, JAEGER J, MUKHIJA S, ISLAM K: AR-100, a novel diaminopyrimidine, can overcome TMP-resistance in staphylococci and streptococci. Proc. Abstr 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):229 (Abstract F–2020).
  • THEN RL, LOCHER H, ANGEHRMN P: AR-100, a novel diaminopyrimidine compound: in vitro activity against Gram-positive and gram-negatiove bacterial pathogens. Proc. Abstr: 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):228 (Abstract F–2018).
  • GOOD CE, WINDAU A, BAJAKSOUZIAN S, JACOBS MR, APPELBAUM PC: AR-100, a novel diaminopyrimidine compound: activity against streptococci. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):229 (Abstract F–2023).
  • HAWSER S, HALDIMANN A, PARISI S, GILLESSEN D, ISLAM K: AR-100, a novel diaminopyrimidine compound: resistance studies in trimethoprim-sensitive and -resistant Staphylococcus aureus. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chernother. (2002):231 (Abstract F–2028).
  • DALE GE, BROGER C, D'ARCY A et al: A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. I Mal Biol. (1997) 266:23–30.
  • KIM OK, FUNG-TOMC J: Patents on 13-lectern antibacterials: January 1999 to March 2001. Expert Opin Ther. Patents (2001) 11:1267–1276.
  • HEBEISEN P, HEINZE-KRAUSS I, ANGEHRN P etal.: In vitro and in vivo properties of Ro 63–9141, a novel broad spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chernother. (2001) 45:825–836.
  • ENTENZA JM, HOHL P, HEINZE-KRAUSS I, GLAUSER MP, MOREILLON P: BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antlinicrob. Agents Chernother. (2002) 46:171–177.
  • JOHNSON AR WARNER M, CARTER M, LIVERMORE DM: In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multi-drug resistant Gram-positive cocci. Antirnicrob. Agents Chernother. (2002) 46:321–326.
  • SWENSON JM, TEN OVER FC: In vitroactivity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus. Antlinicrob. Chen-rather. (2002) 49:845–850.
  • ZHANEL GG, HOBAN DJ: Ketolides in the treatment of respiratory infections. Expert Opin. Phannacother. (2002) 3:277–297.
  • GENIN MJ: Recent progress with oxazolidinone antibacterial agents. Expert Opin. Ther. Patents (2000) 10:1405–1414.
  • JOHNSON AR WARNER M, LIVERMORE DM: In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. j Antlinicrob. Chen-rather. (2002) 50:89–93.
  • JONES RN, BIEDENBACH DJ, ANDEREGG TR: In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. Diagn. Microbial Infect. Dis. (2002) 42:119–122.
  • GRAVESTOCK MB, ACTON D, BROWN S et al.: Structural analogues of AZD2563 I: variations in the tetrahydropyridine N-substituent. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother.(2002):208 (Abstract 1301).
  • GRAVESTOCK MB, BETTS MJ, BLACK E et al: Structural analogues of AZD 2563 II: in vitro evaluation of isoxazoline analogues with 0- and NH-linked C-5 isoxazole side chains. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):209 (Abstract F–1302).
  • GREENE ML, BARBACHYN MR, JACOBSEN SK et al: Synthetic studies leading to the identification of PNU-288034, a potent new oxazolidinone antibacterial agent. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):216 (Abstract F–1333).
  • SCHAADT RD, GREENE ML, SWEENEY MT et al.: In vitro antibacterial activity of PNU-288034, a novel oxazolidinone antibiotic. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):216 (Abstract 1334).
  • ZHOU J, MORTELL K, BORER et al: Combinatorial lead optimization of oxazolidinones: in vitro activity of novel 5-amidomethyl thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):212 (Abstract F–1319).
  • LUEHR GW, WANG S, HACKBARTH CJ et al: Novel antimicrobial pyridazine phenyloxazolidinones. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):212 (Abstract F–1320).
  • RATTAN A, MEHTA A, DAS B et al: In vitro activity of RBx 7644, an extended spectrum investigational oxazolidinone. Proc. Abstr 42nd Intencience Conference Antlinicrob. Agents Chernother. (2002):207 (Abstract F–1288).
  • KELLY LM, HOELLMAN D, JACOBS MR, RATTAN A, APPELBAUM P: Antistaphylococcal activity of RBx 7644, a new oxazolidinone, compared to four other agents. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chemother. (2002):207 (Abstract F–1290).
  • CHANDRASHEKHAR C, SARNAIK HM, RAO NVSM etal.: In vitro and in vivo activity of a novel oxazolidinone - DRF 8417. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):214 (Abstract 1328).
  • SARNAIK HM, CHANDRASHEKHAR C, AMARNATH PVS et al.: In vitro activity of DRF 8417, a novel oxazolidinone, against recent clinical staphylococcal isolates from India. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother.(2002):214 (Abstract F–1327).
  • CHOI S, LEE T, IM W et aL: In vitro antibacterial activity of DA-7867, a new oxazolidinone. Proc. Abstr. 42nd Aderscience Conference Antlinicrob. Agents Chernother. (2002):211 (Abstract 1313).
  • LEE K, YUM JH, YONG D et al: Comparative in vitro activity of a novel oxazolidinone, DA-7867, against recent clinical isolates in Korea. Proc. Abstr. 42nd Intencience Conference Antlinicrob. AgentsChemother. (2002):211 (Abstract F–1312).
  • CLARK CL, JACOBS MR, APPELBAUM PC: Time-kill study of antipneumococcal activity of DK-507k, a new fluoroquinolone, compared to five other agents. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):190 (Abstract F–574).
  • KELLY LM, SMITH K, JACOBS MR, APPELBAUM PC: Antipneumococcal activity of a new quinolone, DK-507k, compared to eleven other agents by MIC methodology. Proc. Abstr: 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):190 (Abstract F–572).
  • LIN G, PATEL M, GUPTE S et al: Time-kill analysis of the antipneumococcal activity of two new quinolones, WCK 771A and WCK 919, compared to five other quinolones. Proc. Abstr 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):186 (Abstract F–559).
  • GUPTE S, PATEL MV, NAIR SC etal.: WCK 771 - eradication efficacy for methicillin sensitive (MSSA) and resistant Staphylococcus aureus (MRSA) skin abscess. Proc. Abstr. 42nd Intencience Conference Antlinicrob. Agents Chernother. (2002):188 (Abstract F–564).
  • UPADHYAY DJ, PATEL MV, GUPTE SV et al: WCK 771 - pharmacodynamic (PD) parameters for MRSA and VISA (vancomycin intermediate S. aureus) eradication in in vitro pharmacokinetic model. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother.(2002):187 (Abstract 563).
  • TANAKA M, YAMAZAKI E, CHIBA M et al.: In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. Antlinicrob. Agents Chemother. (2002) 46:904–908.
  • KWAK J, SEOL M, SO M, CHOI D, JUNG Y: In vitro development of resistant mutants to DW-286a, a new quinolone antibiotic, in Streptococcus prieurnarriae. Proc. Abstr: 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):191 (Abstract F–578).
  • HIMMLER T, HALLENBACH W, MARHOLD A et al: Synthesis and in vitro activity of pradofloxacin, a novel 8-cyanofluoroquinolone. Proc. Abstr. 42nd Intencience Conference Antlinicrob. Agents Chemother. (2002):188 (Abstract F–566).
  • DESHPANDE PK, PATEL MV, GUPTE SV et al: WCK 919 - a fluoroquinolone with potent activity against enterococci. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002):186 (Abstract F–560).
  • GIGLIONE C, PIERRE M, MEINNEL T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mal Microbial (2000) 36:1197–1205.
  • PEI D: Peptide deformylase: a target for novel antibiotics? Emerg. Ther. Targets (2001) 5:23–40.
  • YUAN Z, TRIAS J, WHITE RJ: Deformylase as a novel antibacterial target. Drug Discov. Today(2001) 6:954–961.
  • GIGLIONE C, MEINNEL T: Organellar peptide deformylases: universality of the N-terminal methionine cleavage mechanism. Trends Plant Sci. (2001) 6:566–572.
  • CHEN DZ, PATEL DV, HACKBARTH CJ et al.: Actinonin, a naturally-occurring antibacterial agent, is a potent deformylase inhibitor. Biochem. (2000) 39:1256–1262.
  • BOGGS AF, HECKER SJ: A tour of recent patent applications addressing antibacterial resistance. Expert Opin. Ther. Patents (2002) 12:1159–1172.
  • BOWKER KE, NOEL A, MACGOWAN AP: Comparative in vitro activities of the peptide deformylase inhibitors BB-83698, BB-84887, BB-84888 and BB-85035 against respiratory and skin pathogens. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002):223 (Abstract F–1679).
  • ANDREWS J, JEVONS G, ASHBY J, WISE R: In vitro activity of peptide deformylase inhibitors, a new class of antimicrobials, against Gram-positive respiratory pathogens. Proc. Abstr. 41st Interscience Conference Antimicrob. Agents Chemother. (2002) (Abstract F–353).
  • WOOTON M, HOWE RA, MACGOWAN AP, WALSH TR, BENNETT PM: In vitro activity of BB 83698 and two other peptide deformylase inhibitors compared to ciprofloxacin, moxfloxacin, gentamicin and linezolid against heterogeneous glycopeptide intermediate Staphylococcus aureus (hGISA) and GISA. Proc. Abstr. 41st Interscience Conference Antimicrob. Agents Chemother. (2001) (Abstract F–352).
  • RYDER NS, KUBIK B, MLINERITSCH W et al: NVP-PDF386 (VRC4887), a new antibacterial peptide deformylase inhibitor with potent in vitro activity against drug- resistant organisms. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002):221 (Abstract F–1671).
  • LOPEZ S, HACKBARTH C, KUBO A et al: In vitro microbiological profile of VRC4887 (NVP-PDF386), a potent peptide deformylase inhibitor. Proc. Abstr 42nd Intetscience Conference Antimicrob. Agents Chemother. (2002):221 (Abstract F–1672).
  • NECKERMANN G, FISCHER E, PECANKA R et al.: NVP-PDF386 (VRC4887), a new oral peptide deformylase (PDF) inhibitor: in vivo activities against S. aureus and S. pneumardae infections in mice. Proc. Abstr. 42nd Intetscience Conference Antimicrob. Agents Chemother. (2002):222 (Abstract F–1675).
  • GUILLOTEAU JP, MATHIEU M, GIGLIONE C etal.: The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. I Mo/. (2002) 320:951–962.
  • MARGOLIS PS, HACKBARTH CJ, YOUNG DC etal.: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. (2000) 44:1825–1831.
  • JOHNSON ID, WALLER A, CLEMENTS JM: Characterisation of in vitro-generated Streptococcus pneumaniae mutants with decreased sensitivity to peptide deformylase inhibitors. Proc. Abstr. 42nd Intetscience Conference Antimicrob. Agents Chemother. (2002):223 (Abstract F–1681).
  • NOEL A, BOWKER KE, HOWE RA, MACGOWAN AP: Emergence of resistance in S. pneumardae to peptide deformylase inhibitors in comparison to fluoroquinolones. Proc. Abstr 42nd Interscience Conference Antimicrob. Agents Chemother. (2002):223 (Abstract F–1680).
  • MARGOLIS P, HACKBARTH C, LOPEZ S etal.: Resistance of Streptococcus pneumaniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. (2001) 45:2432–2435.
  • GIGLIONE C, MEINNEL T: Resistance to antipeptide deformylase drugs. Expert Opin. Ther. Targets (2001) 5:415–418.
  • GIGLIONE C, SERERO A, PIERRE M, BOISSON B, MEINNEL T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J. (2000) 19:5916–5929.
  • MILLER WH, SEEFELD MA, NEWLANDER KA et al.: Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. (2002) 45:3246–3256.
  • PAYNE DJ, MILLER WH, BERRY V etal.: Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. (2002) 46:3118–3124.
  • GREEN DW: The bacterial cell wall as a source of antibacterial targets. Expert Opin. Ther. Targets (2002) 6:1–19.
  • DINI C, STACHYRA T, BRAHAM K etal.: Synthesis and In vitro evaluation of riburamycin RU75411: activity against MraY, antibacterial profile and mechanism of action on whole cells. Proc. Abstr. 42nd Intetscience Conference Antimicrob. Agents Chemother. (2002):181 (Abstract F–361).
  • DINI C, DEMASSEY J, DROCHON N etal.: Riburamycin analogues: searching for uracil surrogates to improve MraY inhibition. Proc. Abstr. 42nd Interscience Conference Antimicrob. Agents Chemother. (2002:180 (Abstract F–360).
  • DINI C, BERCHTOLD H, COLLADANT C et al: Fluorinated riburamycins as potent MraY inhibitors: synthesis and in vitro biological evaluation. Proc. Abstr 42nd Intetscience Conference Antimicrob. Agents Chemother. (2002):180 (Abstract F–359).
  • DALY JS, GIEHL TJ, BROWN NC etal.: In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of Gram-positive bacteria. Antimicrob. Agents Chemother. (2000) 44:2217–2221.
  • BUTLER MM, SKOW DJ, STEPHENSON RO et al: Low frequencies of resistance among Staphylococcus and Enterocaccusspecies to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethy1-4'-methylanilino) uracil. Antimicrob. Agents Chemother. (2002) 46:3770–3775.
  • ZHAO L, ALLANSON NM, THOMSON SP etal.: Inhibitors of phosphopantetheine adenylyltransferase. Proc. Abstr. 42nd Intetscience Conference Antimicrob. Agents Chemother. (2002):198 (Abstract 748).
  • ALT ST, TYLER PD, DUNSTER NJ et al: Bacterial phosphopantetheine adenylyltransferases as targets for antimicrobial chemotherapy. Proc. Abstr. 42nd Intetscience Conference Antlinicrob. Agents Chernother. (2002):198 (Abstract 747).
  • LESLIE BW, ALLANSON NM, BARKER JJ et al.: Antibacterial anthranilates with a novel mode of action. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):201 (Abstract F–759).
  • DUNSTER NJ, ALI ST, TYLER PD, GILL AE, LEWENDON A: Pantothenate kinase as a target for new antimicrobial agents. Proc. Abstr: 42nd Interscience Conference Antlinicrob. Agents Chernother.(2002):198 (Abstract F–746).
  • WEBSTER SP, BOTTOMLEY JR, ALI ST et al: Chorismate synthase as a novel target for antimicrobial chemotherapy. Proc. Abstr. 42nd Intetscience Conference Antlinicrob. Agents Chernother.(2002):197 (Abstract F–743).
  • THOMAS MG, ALLANSON NM, LAWSON C et al: Discovery of a series of (2Z)-2-benzylidene-6,7-dihydroxy-1-benzofuran-3(2H)-one inhibitors of chorismate synthase. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):198 (Abstract 744).
  • JOHNSTON D, PACE J, LINSELL M et al: In vitro activity of two novel bactericidal agents against Staphylococcus aureus. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother.(2002):181 (Abstract F–362).
  • FARRINGTON LS, PACE J, LEADBETTER MR et al.: Antibacterial activity of two novel bactericidal molecules against vancomycin-susceptible and - resistant Enterocaccus spp. Proc. Abstr. 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):181 (Abstract F–363).
  • DEBABOV D, PACE J, KANIGA K et al: A bactericidal antibiotic which inhibits bacterial lipid synthesis. Proc. Abstr: 42nd Interscience Conference Antlinicrob. Agents Chernother. (2002):181 (Abstract F–364).
  • MCDEVITT D, PAYNE DJ, HOLMES DJ, ROSENBERG M: Novel targets for the future development of antibacterial agents. Appl. Microbial (2002) 92\(Suppl. 1):28S–34S.
  • ELI LILLY: W00158933: N-acylated derivatives of the vancomycin analogous A82846 glycopeptides. Expert Opiri. Ther. Patents (2002) 12:319–321.
  • ZHU J: Recent developments in reversing glycopeptide-resistant pathogens. Expert Opiri. Ther. Patents (1999) 9:1005–1019.
  • LEADBETTER MR, LINSELL M, FATHEREE P et al: Difunctionalized vancomycin derivatives. Proc. Abstr. 42nd Intetscience Conference Antlinicrob. Agents Chernother. (2002):182 (Abstract F–367).
  • GRIFFIN J, LINSELL M, NOD WELL M etal.: Multivalent drug design: vancomycin dimers. _Proc. AL,tr. 42nd Interscience Conference Arithnicrob. Agents Chernother. (2002):183 (Abstract F–369).
  • ZHANG Y, HILL J, MORYTKO M et al.: Synthesis and biological activity of novel lipophilic tails of lipopeptide. Proc. Abstr. 42nd Intetscience Conference Antirnicrob. Agents Chernother. (2002):178 (Abstract F–348).
  • YU XY, FINN J, HILL J et al: Synthesis and biological activity of ornithine heterocyclic analogs of daptomycin. Proc. Abstr. 42nd Interscience Conference Arithnicrob. Agents Chernother.(2002):178 (Abstract F–349).
  • SIEDLECKI JM, HILL J, FINN J et al: Synthesis and biological activity of benzylic substituted ornithine derivatives of daptomycin. Proc. Abstr. 42nd Interscience Conference Arithnicrob. Agents Chernother. (2002):178 (Abstract F–350).
  • AYSCOUGH A, BECKETT RP, BROOKINGS DC et al: A new series of potent PDF inhibitors displaying broad spectrum activity against respiratory pathogens. Proc. Abstr: 42nd Interscience Conference Arithnicrob. Agents Chernother. (2002):222 (Abstract 1677).
  • BONFIGLIO G, FURNERI PM: Novel streptogramin antibiotics. Expert Opiri. Irivestig. Drugs (2001) 10:185–198.
  • CHUM, MIERZWA R, JENKINS J et al: Isolation and characterization of novel oligosaccharides related to ziracin. I Nat. Prod. (2002) 65:1588–1593.
  • TWOMEY D, ROSS RP, RYAN M, MEANEY B, HILL C: Lantibiotics produced by lactic acid bacteria: structure, function and applications. Aritorde Van Leeuwerihoek (2002) 82:165–185.
  • PAG U, SAHL HG: Multiple activities in lantibiotics-models for the design of novel antibiotics? Curr. Phann. Des (2002) 8:815–833.
  • MACIELAG MJ, GOLDSCHMIDT R: Inhibitors of bacterial two-component signalling systems. Expert Opiri. Investig. Drugs (2000) 9:2351–2369.
  • GAO Y: Glycopeptide antibiotics and development of inhibitors to overcome vancomycin resistance. Nat. Prod. Rep. (2002) 19:100–107.
  • ALKSNE LE: Virulence as a target for antimicrobial chemotherapy. Expert Opiri. Investig. Drugs (2002) 11:1149–1159.
  • WILLIAMS P: Quorum sensing: an emerging target for antibacterial chemotherapy? Expert Opiri. Ther. Targets. (2002) 6:257–274.
  • CHOPRA I: Prospects for antisense agents in the therapy of bacterial infections. Expert Opiri. Irivestig. Drugs (1999) 8:1203–1208.
  • NIELSEN PE: Peptide nucleic acids as antibacterial agents via the antisense principle. Expert Opiri. Investig. Drugs (2001) 10:331–341.
  • GOOD L: Antisense antibacterials. Expert Opiri. Ther. Patents (2002) 12:1173–1179.
  • TORRES VC, TSIODRAS S, GOLD HS et al.: Restoration of vancomycin susceptibility in Enterocaccus faecalis by antiresistance determinant gene transfer. Antlinicrob. Agents Chernother. (2001) 45:973–975.
  • SULAKVELIDZE A, ALAVIDZE Z, MORRIS JG Jr: Bacteriophage therapy. Antlinicrob. Agents Chernother. (2001) 45:649–659.
  • BISWAS B, ADHYA S, WASHART P et al.: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterocaccus faecium. Infect. Inonuri. (2002) 70:204–210.
  • SCHMID MB: Microbial genomics - new targets, new drugs. Expert Opiri. Ther. Targets. (2001) 5:465–475.
  • WOODFORD N, LIVERMORE DM: Can we beat MRSA now we know its genome sequence? Lancet Infect. Dis. (2001) 1:9–10.

Wessites

  • http://www.cubist.com Cubist Pharmaceuticals Company website.
  • http://www.gilead.com/wt/sec/ pr_1031602058 Press Release, Gilead Pharmacuticals (9th September 2002).
  • http://investor.intermune.com/ Intermune Corporate Profile.
  • http://www.ribotargets.com RiboTargets Company website.
  • http://www.iddb.com The Investigational Drugs Database.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.